Is pitubrutinib currently covered by medical insurance?

Pirtobrutinib/Jepali (Pirtobrutinib) is an innovative drug that has attracted much attention in the field of hematological tumor treatment in recent years. It is a highly selective Bruton's tyrosine kinase (BTK) inhibitor and is designed as a new generation of oral drugs that can overcome the resistance problem of traditional BTK inhibitors. Compared with early BTK inhibitors, pitubrutinib has non-covalent binding characteristics, which allows it to maintain its efficacy even in the presence of drug-resistant mutations in the BTK protein, thereby bringing new treatment opportunities to patients with relapsed or refractory hematological tumors.

In terms of indications, Jepali was initially approved by the U.S. FDA for accelerated approval for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), provided that the patient has received at least two systemic treatments, including a BTK inhibitor. Subsequently, its indications were gradually expanded to chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), which also required patients to undergo multiple lines of previous treatments. These hematological malignancies often develop drug resistance or relapse after long-term treatment, and traditional regimens are difficult to provide ideal control. The emergence of pitubrutinib provides new hope for this type of high-risk patients.

In China, the original drug pitubrutinib has been officially approved for marketing recently, bringing more choices to domestic patients with relapsed and refractory hematological tumors. However, it has not yet been included in the national medical insurance catalog, and patients need to bear all costs when purchasing the drug. The main specifications sold on the market are 100 mg, 14 tablets and 4 boards. The overall price is relatively high, which is still an economic challenge for some patients who take medicine for a long time. Whether it can be included in medical insurance will directly affect the accessibility of the drug and the breadth of the people it benefits. From the perspective of the medical insurance negotiation mechanism, new drugs often need to undergo clinical use accumulation and price negotiation before they have the opportunity to be included in the medical insurance catalog. Therefore, it is worth looking forward to pitubrutinib's entry into medical insurance in the future.

Reference materials:https://go.drugbank.com/drugs/DB17472